Mesoblast Limited (MESO) Upgraded to “Buy” by Zacks Investment Research
Mesoblast Limited (NASDAQ:MESO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The brokerage presently has a $6.50 price target on the stock. Zacks Investment Research‘s price target indicates a potential upside of 7.99% from the stock’s previous close.
According to Zacks, “Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. “
A number of other brokerages have also commented on MESO. BidaskClub lowered Mesoblast Limited from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Maxim Group set a $14.00 target price on Mesoblast Limited and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Oppenheimer Holdings, Inc. began coverage on Mesoblast Limited in a research report on Thursday, August 31st. They set an “outperform” rating and a $16.00 target price for the company. Cantor Fitzgerald restated a “buy” rating and set a $20.00 target price on shares of Mesoblast Limited in a research report on Wednesday, August 30th. Finally, ValuEngine lowered Mesoblast Limited from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $13.14.
Shares of Mesoblast Limited (NASDAQ MESO) traded up 4.3172% during midday trading on Wednesday, reaching $6.0191. 47,290 shares of the company’s stock were exchanged. Mesoblast Limited has a 1-year low of $4.01 and a 1-year high of $12.50. The firm has a 50-day moving average of $6.04 and a 200-day moving average of $8.06. The company’s market capitalization is $511.29 million.
Mesoblast Limited Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.